WAM
CYTK icon

Wealthspire Advisors (Maryland)’s Cytokinetics CYTK Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-179
Closed -$1K – 825
2019
Q1 		$1K Sell
179
-36
-17% -$265 ﹤0.01% 2317
2018
Q4 		$1K Buy
215
+199
+1,244% +$1.46K ﹤0.01% 2251
2018
Q3 		$0 Sell
16
-115
-88% -$923 ﹤0.01% 2403
2018
Q2 		$1K Buy
131
+27
+26% +$225 ﹤0.01% 2293
2018
Q1 		$1K Buy
+104
New +$892 ﹤0.01% 2315
2017
Q4 		– Sell
-8
Closed – – 2453
2017
Q3 		$0 Buy
+8
New +$109 ﹤0.01% 2292

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s CYTK Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Cytokinetics (CYTK) in Q2 2019, closing a stake of 179 shares — an estimated $1K sold.

Wealthspire Advisors (Maryland) first reported a position in CYTK in Q3 2017 and held it in 6 quarters. The position peaked at $1K in Q1 2019. 134 funds tracked by Wall St. Rank hold CYTK as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Cytokinetics position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 179 Cytokinetics shares in Q2 2019, an estimated $1K.
  • Wealthspire Advisors (Maryland) first reported a position in Cytokinetics in Q3 2017 and held it in 6 quarters.
  • Wealthspire Advisors (Maryland)'s Cytokinetics position peaked at $1K in Q1 2019.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.